carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 46186827 |
| SCHEMBL ID | 6868305 |
| MeSH ID | M0544918 |
| Synonym |
|---|
| carboetomidate |
| 1257067-10-9 |
| (r)-ethyl 1-(1-phenylethyl)-1h-pyrrole-2-carboxylate |
| 1-[(1r)-1-phenylethyl]-1h-pyrrole-2-carboxylic acid ethyl ester |
| SCHEMBL6868305 |
| J-005271 |
| ethyl 1-[(1r)-1-phenylethyl]-1h-pyrrole-2-carboxylate |
| DTXSID10673042 |
| ethyl 1-[(1r)-1-phenylethyl]pyrrole-2-carboxylate |
| unii-01vla3l1cs |
| 01VLA3L1CS , |
| 1h-pyrrole-2-carboxylic acid, 1-((1r)-1-phenylethyl)-, ethyl ester |
| AKOS040751027 |
| ethyl (r)-1-(1-phenylethyl)-1h-pyrrole-2-carboxylate |
Carboetomidate is an etomidate derivative that produces hypnosis without inhibiting adrenal corticosteroid synthesis. MOC-carboetmidate is a GABA(A) receptor modulator with potent hypnotic activity that is more rapidly metabolized and cleared from the brain.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Carboetomidate is a pyrrole etomidate analog that is 3 orders of magnitude less potent an inhibitor of in vitro cortisol synthesis than etomidate (an imidazole) and does not inhibit in vivo steroid production. " | ( Carboetomidate: an analog of etomidate that interacts weakly with 11β-hydroxylase. Bernhardt, R; Cotten, JF; Ge, R; Miller, KW; Neunzig, J; Raines, DE; Shanmugasundararaj, S; Zhou, X, 2013) | 3.28 |
| "Carboetomidate is an etomidate analog that retains many beneficial properties of etomidate, but it is dramatically less potent as an inhibitor of adrenocortical steroid synthesis. " | ( Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Cotten, JF; Cuny, GD; Forman, SA; Husain, SS; Kelly, EW; Laha, JK; Liu, A; Miller, KW; Nguyen, HH; Raines, DE; Stewart, D, 2010) | 3.25 |
| "MOC-carboetomidate is a GABA(A) receptor modulator with potent hypnotic activity that is more rapidly metabolized and cleared from the brain than carboetomidate, maintains hemodynamic stability similar to carboetomidate, and does not suppress adrenocortical function." | ( In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate. Cotten, JF; Cuny, GD; Kelly, EW; Laha, JK; Le Ge, R; Lin, XJ; Liu, J; Pejo, E; Raines, DE, 2012) | 1.18 |
| "Carboetomidate is an etomidate derivative that produces hypnosis without inhibiting adrenal corticosteroid synthesis. " | ( Carboetomidate inhibits alpha4/beta2 neuronal nicotinic acetylcholine receptors at concentrations affecting animals. Forman, SA; Pejo, E; Pierce, DW; Raines, DE, 2012) | 3.26 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.85) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||